The June 2011 FDA approval of LAVIV™ (azficel-T) for improving moderate to severe nasolabial fold wrinkles was named the No. 3 top story of 2011 in cell and gene therapy and regenerative medicine at the 2012 Cell & Gene Therapy Forum in Washington, D.C, reports LAVIV maker Fibrocell Science, Inc.

“We are delighted and honored that industry leaders attending the 2012 Cell & Gene Therapy Forum have recognized the FDA approval of LAVIV and we hope we continue to impress the industry with our innovations in upcoming years,” said David Pernock, Fibrocell Science Chairman and CEO, in a press release.

LAVIV uses a patient’s own fibroblast cells to create a personalized filler. It is the first and only personalized cell therapy approved by the FDA for aesthetic use.

LAVIV is now available in major metropolitan areas throughout the US exclusively through board-certified dermatologists and plastic surgeons that have been trained by Fibrocell Science on the treatment process.

For more information about LAVIV, see the Full Prescribing Information at